Dutch nanomedicine company Cristal Therapeutics has expanded the financing round initiated by Thuja Capital and BioGeneration Ventures by adding two investors, Nedermaas Ventures and Innovatie Fonds Limburg.
The proceeds will enable the company to progress the CriPec docetaxel as its first product into clinical development.
Nedermaas Ventures investment manager Jeffrey Lutje Spelberg said, “The relocation of Cristal Therapeutics to Maastricht illustrates that the Euregio presents various attractive elements for life sciences companies, and we look forward to additional interaction between parties at the Maastricht Health Campus, the Chemelot Campus and other key players in the Euregio.”
Nedermaas makes seed investments in technology companies operating in the life sciences, biotechology, medical devices, agriculture and food and chemistry sectors.
Copyright © 2013 AltAssets